Publications

Joint research collaboration between Merck, Purdue University, Argonne National Laboratory, and Improved Pharma

WEST LAFAYETTE, Ind., Nov. 9, 2023 /PRNewswire-PRWeb/ -- Amorphous drugs have become a critical component in modern medicine and in drug development pipelines. Understanding the structural basis of phase stability of these materials is critical in the design of drug products, and yet remains a challenge due to the limited availability of high-resolution analytical tools. In Read more

Joint research collaboration between Merck, Purdue University, Argonne National Laboratory, and Improved Pharma2024-05-30T16:00:34+00:00

The Structure of Liquid and Glassy Carbamazepine

To enhance the solubility of orally administered pharmaceuticals, liquid capsules or amorphous tablets are often preferred over crystalline drug products. However, little is known regarding the variation in bonding mechanisms between pharmaceutical molecules in their different disordered forms. In this study, liquid and melt-quenched glassy carbamazepine have been studied using high energy X-ray diffraction and Read more

The Structure of Liquid and Glassy Carbamazepine2022-11-21T19:18:36+00:00

Ritonavir Form III: Lightning strikes twice at the same time, 137 miles apart

WEST LAFAYETTE, Ind. (PRWEB)September 13, 2022 Developing new tools and advancing pharmaceutical development is a key part of Improved Pharma’s mission. In 2021, Improved Pharma had the unique opportunity to start polymorph screening research projects in close collaboration with Varda Space Industries with the intent of advancing pharmaceutical product manufacturing. As a result, the Read more

Ritonavir Form III: Lightning strikes twice at the same time, 137 miles apart2022-09-19T13:47:51+00:00

Improved Pharma Contributes to Paper Advancing the Study of Sameness of Amorphous Materials

WEST LAFAYETTE, IND. (PRWEB) JANUARY 03, 2022 Improved Pharma’s continued collaboration with expert colleagues in the field of amorphous studies has resulted in a new publication. The article can be downloaded for free by clicking on this link. This free access expires on February 11, 2022. This article highlights the extreme value of using synchrotron x-ray Read more

Improved Pharma Contributes to Paper Advancing the Study of Sameness of Amorphous Materials2022-01-17T20:22:19+00:00

Improved Pharma presenting at AAPS 2021 PHARMSCI 360 with Four Posters

WEST LAFAYETTE, Ind. (PRWEB)October 15, 2021 Starting Monday, October 18th, Dr. Susan-Bogdanowich-Knipp, President of Ravine Pharmaceuticals and consultant with Improved Pharma, will present “Polymorph Screen of Newly Discovered Salts of Bedaquiline”. The poster (M2142) is part of the Manufacturing and Analytical Characterization – Chemical – Drug Substance Manufacturing and Development – Crystal Structure/Polymorph Screening Read more

Improved Pharma presenting at AAPS 2021 PHARMSCI 360 with Four Posters2022-02-10T21:51:55+00:00

Additional Research on Bedaquiline Salts recently published in Acta Crystallographica

Improved Pharma is pleased to announce an additional open-source publication describing the structures of Bedaquiline maleate salts that is now available to download.  Previously, our lab was able to identify promising new benzoate salts of Bedaquiline, a first-in-class drug used in the treatment of tuberculosis.  This current publication describes the successfully solved crystal structures obtained from Read more

Additional Research on Bedaquiline Salts recently published in Acta Crystallographica2022-01-17T20:25:52+00:00

Improved Pharma announces recent publication on expediting preclinical formulation development of amorphous lapatinib using mini-tab formulations in pediatrics

Dr, Stephen Byrn, CSO of Improved Pharma, was a key contributor to a recent publication describing the usefulness of mini-tablets in monitoring the dose-response of lapatinib solid amorphous dispersions in juvenile pigs.   Juvenile pigs have been well-established as an effective pediatric model.  The use of mini-tabs allowed for dose flexibility as the the amount of tablets dosed could Read more

Improved Pharma announces recent publication on expediting preclinical formulation development of amorphous lapatinib using mini-tab formulations in pediatrics2022-01-17T20:26:32+00:00

Improved Pharma announces new publication on amorphous dispersions

A recent collaboration with our colleagues further advances the field of X-ray pair distribution function analysis applied to the analysis of amorphous solid dispersions. In this paper, we present the results of different polymer:flubendazole drug dispersions exposed to aging conditions. We discovered that if the polymer has ion-base interactions with the drug, the resulting Read more

Improved Pharma announces new publication on amorphous dispersions2022-01-17T20:27:17+00:00

Recent research on bedaquiline selected for the November cover of Acta Crystallographic

Improved Pharma is pleased to announce the open-source publication of research into finding new salts of bedaquiline, an important drug for the treatment of tuberculosis. The drug is currently marketed in the US as the fumarate salt. Our team discovered several new salts, and the crystal structures of two benzoate salts are described in Read more

Recent research on bedaquiline selected for the November cover of Acta Crystallographic2022-01-17T20:39:31+00:00

Improved Pharma presenting at AAPS 2020 PHARMSCI 360 with Rapid Fire Presentation and Poster

WEST LAFAYETTE, IND. (PRWEB) OCTOBER 26, 2020 Interact with us via poster number 924440 and the Advances and Innovation in Formulation Development Rapid Fire session. On Wednesday October 28th, Dr. Pamela Smith, COO of Improved Pharma, will present “Synchrotron-Based Formulation Development” in the Rapid Fire: Formulation and Quality – Chemical session. Those registered for the Read more

Improved Pharma presenting at AAPS 2020 PHARMSCI 360 with Rapid Fire Presentation and Poster2022-02-10T21:53:17+00:00
Go to Top